

## Index

### a

- ABC transport proteins 24, 25
  - P-glycoproteins 24
- abdominal pains 199
- absorption, distribution, metabolism, excretion/toxicity (ADMET) 138
- academic/industrial environment 136
- acceptor/donor amino acid residues 80
- acceptor proteins 291
- acetyl-CoA 83, 284, 290
- O-acetylserine sulfhydrylase 85
- Actinobacillus pleuropneumoniae* 441
- active ligands 333
- active pharmaceutical ingredients (APIs) 140, 142, 143
  - compounds 141
  - descriptor values 143–145
  - distribution 142
  - origin classes 143–145
- active salvage pathway 217
- activity-enriched datasets 324, 326
- acyliminium ion cyclization method 305
- adaptation/stochastic variation 431
- adaptive immune response system 163, 164
  - regulation 164
- adaptive/innate responses 164
- adverse drug reactions (ADR) 102
- aerobic environment 312
- aerobic respiratory chain 359
- affinity chromatography 238, 268
- African/American trypanosomes 189, 211, 314
- African sleeping sickness 87, 212
  - causative agents 212
- agar plates 348
- AGC kinase family 265
  - PfPKA-c 265
  - PfPKA-R 265
- PfPKB 266
- PfPKG 266
- agricultural pests 19
- AIDS 278
- aldol reaction, Sn-mediated 467
- aliphatic compounds 308
- alkylaminoalkanethiosulfuric acids 301
- allylic bromide synthesis 464
- allyl magnesium bromide 460
- Alzheimer's diabetes mellitus 241
- Alzheimer's disease 264
- amebic colitis 184
- amide derivatives 304
- aminoacetonitrile derivatives (AAD)
  - toxicity 20
- amino acids 51, 231, 304, 389
  - mutations 253
  - residues 228, 231
  - rich extension 264
  - side-chains 83
- $\alpha$ -aminoacrylate intermediate 84
- aminoacyl tRNA molecules 400
  - inhibitors 382
  - synthetases 403
- aminoalkanethiosulfuric acids 306, 307, 309
- aminoethanethiosulfuric acids 305
- anaerobic bacteria 82
- anaerobic energy metabolism 91, 92
- anaerobic glycolytic fermentations 87
- anaerobic mitochondrial electron transport pathway 361
- anaerobic nematode 362
- anaerobic pathogens 80
- anaerobic protozoa 76, 80, 81, 82
  - *Entamoeba histolytica* 76, 82
  - *Giardia lamblia* 76
  - glycolysis 77
  - metabolic aspect 76

- *Trichomonas vaginalis* 76, 82
- *Tritrichomonas foetus* 76
- analytics/physicochemical assays 112
- anaphase-promoting complex (APC) 240
- Angiostrongylus costaricensis* 343
- animal health programs 9
  - health market 99
- animal parasites 45, 106
  - fleas 106
  - helminths 106
  - *heterakis gallinarum* 45
  - *heterodera glycines* 45
  - ticks 106
- anopheles gambiae* 278
- anopheline mosquito 177
- antagonistic drug action 68
- antagonist targets techniques 65
- anthelmintic drugs 18, 357, 358, 363, 364
  - benzimidazoles 17
  - chemical optimization 357
  - classes 17
  - discovery 9, 18
  - macrocyclic lactones 17
  - mode of action 18
  - nicotineric agonists 17
  - nonspecific resistance mechanisms 24
  - resistance issue 17
  - specific resistance mechanisms 21
  - targets 357
  - templates 8
- anthelmintics target, GABA receptors 12
- antibacterial agent 386, 418
  - bacterial expression profiling 381
  - cell assay 417
  - determination/validation 381
  - drug discovery 383, 415, 417, 418
  - molecules 384
  - MW, distribution plot 148
  - therapies 386
- Antibacterials Genome Research & Development 377
  - impact 377
- antibiotics 393, 395, 455
  - classes 394
  - molecular structures 395
  - pathogens 387
  - resistant bacteria 375, 386, 393
  - status 393
- antigen derived epitopes 163
- antigen-presenting cell 163, 164, 429
- antigen receptor 164
- anti-infective agents 75
- anti-infective drug discovery, current paradigm 417
- antileishmanial drug target 233
- antimalarial drugs 178, 249, 250, 253, 254, 310
  - activity 453
  - drug discovery 380–381
- antimicrobial peptides 199
  - cathelicidins 199
  - $\theta$ -defensins 199
  - magainins 199
- antimicrobial screening programs 376
- antimony-containing compounds (pentostam) 212
- antinematode drugs 357
  - classes 358
- antinfertious/parasitic drugs 118
- antiparasitic/anti-infective molecular targets 108
- antiparasitic compounds 13
  - activity 309
  - agents 75
  - assays 62
  - classes 155
- antiparasitic drug 3, 4, 5, 10, 45, 60, 61, 62, 75, 94, 117, 119, 170
  - approaches 117
  - development 239
  - discovery 59, 60, 110, 138
  - features 62
  - identification/validation 59
  - research 59
  - screening 3
  - special challenges 62
  - structure 118
  - target-based approach 60
  - use 4, 117
- antiparasitic leads 118
- antiparasitic market products 61
- antiparasitic screening target 62, 63, 64
  - assays 100
  - properties 62
- antischistosomal compounds 316
- antischistosomal drug discovery 302, 310
- antisense RNA inhibition 198
- antituberculosis (antiTB) drugs 415, 423, 432, 433
  - chemical structures 423
  - treatment 431
- apical secretory organelles 184
- apicomplexan parasites 88, 184, 190, 285
  - *Plasmodium falciparum* 6, 88
  - *Toxoplasma gondii* 88
- apicomplexan protozoa 89
- apicoplast, 286, 277, 288
  - membrane 286, 290

- metabolites 288
  - mis-segregation 286
  - apicoplast-generated pyruvate, *see* FAS II pathway
  - apicoplast-localized proteins 286
  - apicoplast-resident pyruvate dehydrogenase 289
  - apicoplast-resident synthesis 291
  - Armillaria mellea* 458
  - aromatic compounds 89
  - aromatic hydroxamates 88
  - aromatic motif 363
  - aromatic ring 308
  - arsenic-based drug 34
  - artemisinin derivatives, antischistosomal activity 309
  - asexual blood-stage malaria parasite 178, 180
  - aspartic protease inhibitor, activity 198
  - ATP-binding proteins 229
    - active site 263
    - binding site 229, 241
    - dependent ligases 218
    - dependent phosphofruktokinase 77
    - dependent reaction 86
    - grasp proteins 218
    - homologs 218
  - attenuated rabies vaccine 169
    - vaccine strain 168
  - attenuated strains, infection 167
  - aurora kinases 239
    - inhibitors 239, 240
  - auramine-rhodamine fluorescent staining 425
  - auxillary pathways 286
- b**
- β-lactam antimicrobials 399
  - B-specific inhibitors 186
  - β-tubulin 12
    - sequence 26
  - Babesia-derived proteases 183
  - Babesia divergens* 169
    - infections 167
  - bacterial antigens 389
  - bacterial enzyme 77
  - bacterial genome 376
    - sequence 442
  - bacterial pathogens 386
    - infections 384, 387, 393
  - bacterial ribosome 399
  - bacterial species 163
  - bacterial toxins 391
  - bacterium-type FAS II 290
  - basidiomycete sesquiterpenoids 456
  - BCUT matrix analysis 108
  - benzimidazole 23
    - binding site 23
    - resistant nematodes 23
  - binding site residues 263
  - bioactive substances 62, 125
  - biochemical/cellular assays 99
  - biocide compounds 128
    - ionophores 128
    - uncouplers 128
  - bioinformatic analysis 50
    - database searches 50
    - multiple sequence alignments 50
    - tools 65, 90
  - bioinformatic sequence 48, 51
    - analysis 51
  - biological assay systems 99, 106
  - biological sequence data, *see* Genomic filtering
  - biological systems 219
  - biology-based intellectual property 8
  - biology-driven drug discovery 124
  - bioscreen scores 367
  - biosynthetic process 82
  - biotinylated fluorophosphonate probe 184
  - bipartite targeting domain (BTD) 286
  - Birch reduction 462
  - black widow spider venom 345
  - BLAST alignments 50
  - blood-stage parasites 179
  - blood-stage schizont rupture 180
  - bloodstream/cerebrospinal fluid 228
  - bloodstream form (BSF) trypanosomes 240
  - bovine cells 190
  - bovine pathogen 441
  - bovine respiratory disease (BRD) 453, 455
  - broad-spectrum antibiotics 401
    - carbapenem 401
    - ceftaroline 401
    - cephalosporin 401
    - tigecycline 400
  - broad-spectrum antiparasitic drugs 119
  - broad-spectrum protease inhibitors 179, 183
  - bronchocentric granulomatosis 425
  - bronchovascular/mediastinal structures 429
  - 2-(butylamino)-1-phenyl-1-ethanethiosulfuric acid 308
- c**
- Ca-dependent kinase activity 267
  - Caenorhabditis elegans* 20, 22, 46, 94, 123, 346, 347, 348, 350, 352
    - emodepside action 346
    - latrophilin receptor 347

- L4 larval stages 348
- mutagenesis protocols 22
- mutant strains 22
- calcium-activated K<sup>+</sup> signaling pathway 352
- voltage-gated K<sup>+</sup> channel 19, 350
- calcium/calmodulin antagonists 267
- calcium-dependent channels 397
- calcium-dependent protein kinase family 267
- PfCDPK1 267
- calpain-like cysteine proteinases 185
- cAMP-dependent pathway 265
- cancer chemotherapy 249
- cancer therapy, inhibitor 212
- CAP3 software 48
- cardiovascular disease 249
- casein kinase 1 (CK1) enzymes 237
- casein kinase family 268
- PfCK1 268
- catalyst-mediated processes 305
- catalytic hydrogenation 459
- cathepsin L-like protease 189
- cattle pathogen 183
- *Babesia bovis* 183
- CDK-activating kinase (CAK) 235, 262
- post-translational control 235
- schematic presentation 235
- CDK inhibitors 236, 237
- flavopiridol 236
- olomoucine 236
- phosphorylation site 263
- cDNA 182, 344, 385
- cell-binding domain 180
- cell-mediated immunity 278
- cell permeable peptidyl ketone inhibitor 186
- cell surface receptors 163
- cellular assays 435
- cellular immune response 162
- cell wall synthesis 402
- central nervous system toxicity 25
- cGMP signaling pathway, binding sites 266
- Chagas' disease 33, 34, 35, 36, 180, 185
- acute 35
- chronic 35
- indeterminate 35
- Chagas' drugs 214
- benznidazole 214
- nifurtimox 214
- chemical parameters 129
- aqueous solubility 129
- volatility 129
- chemoinformatic/molecular modeling techniques 47
- chemoinformatic tools 128, 359
- chemotherapeutically controlled infection 166
- chemotherapeutic drug 170
- chiral enediyne, retrosynthetic analysis 463
- Chlamydomonas reinhardtii* 238
- chloride-gated ion channel 91
- chlorinated hydrocarbons/  
organophosphates 4
- chloroplast-like malarial organelle 178
- chorismate synthase 89
- CK enzyme 238, 268
- inhibitors 238
- coagulase-negative staphylococci 387, 393
- coagulation systems 163
- cocciostatic drugs 166
- cognate interactions 162
- compound logistics 111, 112
- handling/supply 111
- computational algorithm analysis 390
- computational/experimental approaches 376
- computer-aided modeling 401
- computer-based methods 323
- contaminated food 186
- Cooperia oncophora* 344
- cost-benefit analysis 6
- cowpox induced immunity 167
- cross-species vaccination 167
- C-terminal domains 181
- inhibitory regions 268
- pyruvate/PEP binding site 79
- cyclic octadepsipeptides 351
- cyclin-dependent kinases 234
- cyclooctadepsipeptides 339, 344
- mechanisms of action 344
- PF1022A 20
- cyclohexane ring 303
- cysteine/aspartic proteases 178
- cysteine biosynthetic pathway 76, 82, 83, 84
- cysteine endopeptidases 178
- cysteine protease family, schematic presentation 196
- cysteine proteases (E64) 182, 185, 186, 188, 198, 314
- inhibitors 181
- cysteine proteinase genes 185, 186
- EhCP1 185
- EhCP2 185
- EhCP5 185
- cysteine synthase 82
- cystic fibrosis 404
- cytokines gamma-interferon  $\gamma$ (-IFN) 164
- cytoplasmic acidic vesicles 345
- cytosolic serine protease 198

**d**

- daptomycin 397
- datasets prefiltering 329
- DBL-EBP family 179
- DDT 6, 165
- de novo* synthesis 290
- dense granule-like organelles 179
- 1-deoxy-D-xylulose-5-phosphate reductoisomerase 90
- Dess–Martin periodinane 465
- detoxifying enzymes, P450 21
- 2D gelatin gel electrophoresis 182, 446
- diabetes 177, 229, 239, 241, 264
- diagnostic methods 381
- diastereomeric salt/reacylation 305
- diazoacetyl-norleucinemethylester 198
- dideoxy chain termination sequencing technology 443
- Diels–Alder reaction 461
- dimethylallyl pyrophosphate 289
- dimethyl sulfoxide 110
  - stock solutions 110, 111
- discovery paradigms 7
- discovery synergies 8–10
- disease-focused treatment 455
- disease-relevant parasitic stages 124
- disulfide bridge 52
- dithiol-containing medium-chain fatty acid 290
- diverse assay technologies 112
  - cellular assays 112
  - enzymatic 112
  - ion channel 112
  - microbial parasite assays 112
  - protein-protein binding 112
- DNA microarrays 381, 385
  - oligonucleotide-based arrays 385
  - PCR product-based arrays 385
  - technology 385
- DNA replication 263, 403
  - bacterial DNA gyrase 403
  - topoisomerase IV 403
- DNA sequences 47, 169, 380, 385, 446, 447
  - amplification/sequencing 445
  - metabolism 389
  - vaccination 388
- DNDi 36, 38, 41
  - data management 41
  - decision matrices 40
  - discovery manuals 38
  - lead optimization 36
  - schematic presentation 40
- docking experiments 48, 53, 329
- dopaminergic receptors 327
- double-stranded RNA (dsRNA) 66
  - interference 211
- DOXP synthase (Dxs) 289
- D-phenyllactic acids 339
- Drosophila melanogaster* 46, 50, 51, 53, 54, 61, 62, 64, 66, 123
  - genome 64
  - phenotypic effect 61
- drug addiction gene 168
- drug design 8, 70
  - mechanism-based 119
  - process 324
  - structure-based 8
- drug discovery process 4, 8, 10, 17, 25, 45–48, 59, 119, 135, 136, 182, 302, 334, 421, 434
  - contribution 25
  - mechanism-based approaches 8
  - mode of action 18
  - nonspecific resistance mechanisms 24
  - specific resistance mechanisms 21
  - key technologies 45
  - schematic presentation 48
- drug-mediated interference 183
- drug-resistant parasites 165
  - nematodes isolation 23
- drug-resistant strains 21
  - drug-resistant TB 417
  - MTB strains 416
- drug metabolism 24
  - cytochrome P450 24
- drug resistance 249
  - genes 22
- drug targets 3, 63, 213, 301
  - validation 213
- DV-located metalloprotease 178
- Dxr inhibition 289
- dynamic polymers, *see* microtubule

**e**

- ectoparasitic field 62, 129
- ectoparasiticides/agrochemical insecticides 6, 129, 146, 147
  - ivermectin 6
- egg-laying muscles 348
- Eimeria* parasites 166
- electron transport chain 360, 362
- electrophysiological/binding studies 344
- emodepside 343
  - anthelmintic activity 343
  - interactions 346
  - parasites 23
  - receptor 349
  - SLO-1 349
  - strains 349

- EMS chemical mutagenesis 349  
 endocytotic vesicles 238  
 endo/ectoparasites 50, 51, 104  
   – orthologous sequences 50  
 endogenous glutamate transmitter 94  
 endothelial cells 163  
 energy metabolism 77, 359  
 energy-transducing mechanism 360  
 engineering industries, car industry 136  
 enoyl-acyl carrier protein (ACP)  
   reductase 290  
*Entamoeba histolytica* 6  
   – enzyme 77  
   – genome 85  
   – pathogenicity 185  
 enumeration processes, impact 328  
 enzymatic assays 181  
 enzymatic synthesis 288  
 epoxide cysteine proteinase inhibitor 185  
 erythrocyte-binding ligands 179  
 erythrocytic cycle 177  
 erythrocytic schizogony 262  
*Escherichia coli* 289  
 EST sequences 45, 50  
 eukaryotic cells 18  
 eukaryotic protein kinases (ePK) 228  
 experimental methods 138  
 expressed sequence tags (ESTs) 48  
 extrapulmonary tuberculosis 429
- f**
- FabF/FabH inhibitors 402  
 FACS analysis 388  
 farnesyl pyrophosphate synthase (FPPS)  
   288  
   – inhibitor 289  
 FAS II pathway 289  
   – enzymes 290  
   – gene 290  
   – inhibitors 290  
 fatty acid/lipoic acid biosynthesis 289  
   – pathway 402  
 Fd redox system 291  
 Fe-binding protein 189  
 fermentation products 3  
 ferredoxin-linked enzyme 76  
 ferredoxin redox system 291  
 flavin-containing glycerol-3-phosphate  
   dehydrogenase 87  
 flavin-containing trypanothione reductase 86  
 flock immunity, development 167  
 fluorogenic peptides 181  
 FMRFamide-like peptides (FLPs) 13  
 focused libraries 110
- fosmidomycin/NADPH, H-bond network 92  
 free-living amoeba, *Naegleria fowleri* 77  
 Freund's complete adjuvant (FCA) 161  
 fructose 6-phosphate 77  
 fruitfly sequence 53  
 function-based screens 124
- g**
- GABA-gated chloride channel, fipronil 64  
 GABA receptor 21, 344  
 GAL4 activator 66  
 GAL4 driver 66, 68  
 GAL4 enhancer trap insertion database  
   (GETDB) 68  
 GAL80 repressor 66  
 $\gamma$ -proteobacteria 441  
 gap-closure 441, 445  
   – PCR-based strategies 445  
   – workflow 441  
 gastrointestinal mega-syndromes 180  
 gastrointestinal nematodes 343  
 gastrointestinal/respiratory systems 187  
 gastrointestinal tract physiology 126  
 gene expression systems 379  
 GENESWITCH system 66  
 genetic algorithms 332  
 genetic interaction 65  
 genome analysis 375, 389  
 genome-based technologies 376, 384  
 genome evolution 376  
   – gene gain 376  
   – gene loss 376  
 genome sequences 375, 381, 388  
   – analysis 381  
 genome sequencing projects 212, 384, 441  
 genome-wide protocols 12  
 genomic filtering 47  
 genomics-based approaches 11  
 genomics gap closure 443  
 genomics Genlight software 48  
 genotoxic drugs 34  
 genotypic/phenotypic data, statistical  
   analysis 142  
 genotyping method 385  
*Giardia lamblia* 199  
   – infection 168  
 Giemsa-stained smears 183  
 global expression analysis 382  
 globular proteins 217  
 glutamate-gated chloride channels  
   (GluCl) 21, 64, 93  
 glutathione reductase 312  
 glutathionylspermidine synthetase  
   (GspS) 213

- glycolysis-derived phosphoenolpyruvate (PEP) 288
- glycopeptides 397
- glycosomal pyruvate phosphate dikinase 79
- glycosylphosphatidylinositol anchor 185
- GMGC kinase family 256
- Pfcrk-1 263
  - PfGSK3 264
  - Pfmmap-1 256
  - Pfmmap-2 256
  - Pfmrk 262
  - PfpK5 263
  - PfpK6 262
- golgi-associated proteins 238
- cisterns 181
  - snapin 238
- G protein-coupled receptor (GPCR) 344, 351
- GPx-type peroxidases 218, 220
- gram-negative pathogens, MRSA 400
- bacteria efflux 404
- gram-negative species 379
- gram-positive model organism 378
- *Bacillus subtilis* 378
- gram-positive multidrug-resistant pathogens 397
- gram-positive pathogens 379, 383, 395, 396, 398, 403
- *Staphylococcus aureus* 379
  - streptococci 398
- growth-inhibiting compounds 419
- GSH reductase, structures 86
- GSH system 213
- derivatives 219
- guinea pig 422
- gut-dwelling parasitic nematode 359
- h**
- Haemophilus influenzae* 397
- Hageman factor 163
- HAP pathogen 442
- hard-to-treat diseases 211
- African sleeping sickness 211
  - Chagas' disease 211
- H-bond acceptors/donors 109, 138, 142
- H-bond network 83
- HC110-R disposition, schematic view 345
- heat-killed bacteria 161
- HeLa cells, CP65 182
- $\alpha$ -helical carboxy-terminal lobe 229
- Heligmosomoides polygyrus* 342
- helminths 91
- drug initiative 7, 315
  - infections 166
  - parasitic 314
- hematin accumulation 307
- heme pathway 284
- herpes virus of turkey (HVT) 167
- heterocyclic moiety 363
- heterocyclic ring system 363
- heterodimeric receptor complexes 67, 83
- high-activity anti-retroviral therapy (HAART) 188
- high-dose infection 167
- high-level macroschizont-specific expression 196
- high-performance computing (HPC) platforms 324
- high-throughput liquid chromatography (HPLC) 111, 141, 465
- mass spectroscopy 111
- high-throughput molecular docking methods 46, 136, 285, 291, 323, 325, 326
- approaches 54
  - bioinformatics 46
  - method 335
  - process 330, 333
  - relevant binding pockets 327
  - schematic representation 326
  - workflow 328
- high-throughput screening (HTS) 61, 70, 106, 179 313, 323, 302, 383, 386
- assay 63, 383
  - compatible enzymes 420
  - libraries 110, 324
  - methods 455
  - screening 63, 64
  - systems 13
  - technology 323
- high-throughput technologies, pyrosequencing 47
- hit-to-lead process 109
- HIV-infected patients 170
- holoenzyme complex 87
- homodimeric enzyme 78, 80
- homodimeric PPDks 79
- homologous enzymes 185
- Homo sapiens* 278
- horse gastrointestinal nematodes 18
- host cell hemoglobin 178
- host defense mechanisms 159
- HRD motif 231
- human African trypanosomiasis (HAT) 33, 34, 35, 39, 240, 189, 301
- human cysteine protease cathepsin 182
- human embryonal kidney cell assay (HEK293) 328, 346
- human filariasis 4

- human health drug discovery 59, 61, 62, 63
    - simulation 62
  - human kinase 251, 254
    - drug discovery efforts 251
    - inhibitors 254
  - human necrotizing granulomata 422
  - human parasite-targeted screening stream 9
  - human target proteins 327
  - human trematocidal compound 120
  - human vaginal epithelial cells 182
  - human/veterinary drugs 153
    - health 125
    - helminth infections 17
  - hybridization reaction 385
  - hydrindane moiety 459
  - hydroperoxide metabolism 213, 215
  - hydroperoxides detoxification 211
  - hydrophilic drugs 432
  - hydroxamate group 91
  - hydroxamic acid derivatives 402
- i**
- illudoid family 457
  - illudol 460, 461, 462
    - Matsumoto's synthesis 460
    - Semmelhack's synthesis 461
    - Vollhardt's synthesis 462
  - imaging mass spectrometry (IMS) 434
  - immune response 164, 221, 424
    - T-helper 1 cells (Th-1) 164
    - T-helper 2 cells (Th-2) 164
  - immune system 197
  - immunoelectron microscopy 181
  - immunogenic epitopes 164
  - immunology 161
    - adaptive immunity
    - natural immunity 162, 164
  - immunomodulating cytokines 159
  - immunotherapy/vaccine development 387
  - incubation period 163
  - industrial drug discovery 136
  - infectious diseases 117, 165
    - chemotherapeutic treatment 165
    - control 165
  - inflammatory disorders 229
  - inflammatory reaction 427
  - inhibitor binding sites 84
  - inhibitory ionotropic receptors, GluCl<sub>s</sub> 93
  - inhibitory scaffolds 254
  - innate immune responses 163
  - in silico* gap closure 444, 445
    - MUMmer dot plot 444
    - pharmacophore approaches 328
  - in silico* screening methods 54, 324, 328, 334
    - homology modeling 54
    - molecular docking 54
    - sequence analysis 54
  - in silico* tools 121
    - molecular docking 121
    - molecular modelling 121
    - pharmacophore design 121
    - virtual screening 121
  - integral membrane proteins 179
    - AMA1 179
    - PTRAMP 179
  - intellectual property 111
  - interleukin 2 163, 164
  - intra-abdominal infections 400, 401
  - intracellular apicomplexan parasite 278
  - intracellular efflux pumps 404
  - intra-erythrocytic growth 177
  - introns 25
  - in vitro* antischistosomal activity 307
  - in vitro* assay 107, 323, 336
    - derivatives 127
  - in vitro* bactericidal activity 398
  - in vitro/in vivo* assays 435
  - in vitro* kinase activity 269
  - in vitro* lipophilicity activity 365, 367
    - correlation 365, 367
  - in vitro* therapeutic index 255
  - in vivo* antiparasite screens 59
  - in vivo* biological activity 125
  - in vivo* pharmacodynamic studies 122
  - in vivo* screens 7
  - iron-sulfur clusters 361
  - isoleucyl-tRNA synthetase (IleS) 382
  - isopentenyl pyrophosphate 89
  - isoprenoid biosynthesis pathway 90, 288, 291
    - steroids/dolichols/quinones 89
  - isoquinolinesulfonamide compound 268
  - ivermectin/moxidectin treatments 24
  - ivermectin-resistant nematodes 339
- k**
- killed vaccines/adjuvants 161
  - kinase activation cascade 256
  - kinase inhibitors 251
  - kinetoplastid parasites 6, 197, 234, 312
    - *Cryptosporidium parvum* 6
    - *Entamoeba histolytica* 6
    - *Giardia lamblia* 6
    - *Leishmania donovani* 6, 212, 312
    - *Trypanosoma cruzi* 6
    - *Toxoplasma gondii* 6

- *Trichomonas vaginalis* 6
- *Trypanosoma brucei* 6, 312
- kissing bug 35
- knockout experiments 60
- knockout mutants 65

## I

- Lactarius atlanticus* 459
- large-scale interactomic maps 387
- latrophilin 344
  - G protein-coupled receptors 348, 357
- $\alpha$ -latrotoxin signaling 345
- lead compounds 108
- lead discovery project 107
- lead optimization 126, 130, 362
  - factors 130
  - process 101
  - projects 127
  - workflow 126, 127, 128 130
- Leishmania infantum* infection 169, 170
- Leishmania mexicana* parasites 168
  - deletion mutants 233
  - LmxMPK4 232
- Leishmania promastigotes* 197
- leishmaniasis chemotherapy 197
- leukocytes 163
- levamisole-resistance genes 22
  - acr-8 22
  - lev-1 22
  - lev-8 22
- ligand-based virtual screening
  - approaches 323, 329
- ligand binding affinity 332
- ligand-gated anion channels 21
- ligand-gated ion channel, schematic representation 94
- light microscope 161
- lipoic acid synthesis 290
  - 3D structures 290
  - LipA 290
  - LipB 290
  - synthase 291
- lipoamide dehydrogenase 219
- lipophilic drugs 364
- Litomosoides sigmodontis* 343
- long-chain fatty acid esters 459
- low-affinity inhibitors 262
- low-dose infections 166, 167
- low-throughput systems 7
- $\alpha$ -ITX-HC110-R 346
- L-serine O-acetyltransferase 83
- lungworm parasites 168
- lymphoproliferative disorder 190
- lysosome-like digestive vacuole 178

## m

- macrocyclic lactones 9, 12, 21, 25, 94, 147, 340, 358
  - antinematodal drugs 94
- macroschizont membrane 196
- malaria 183, 250, 277, 278, 279
  - chloroquine 277
  - drug discovery 251
  - drugs/drug combinations 279–284
  - drug resistance 253
  - eradication program 165
  - infection 166
  - malaria kinase drug discovery 254, 255
    - considerations 254
    - coupling target 255
    - homology 251
  - malaria kinome 249
  - malarial casein kinase activity 268
  - malarial infection 180
  - malarial kinases 249, 251, 252, 253, 254, 255, 256
    - characteristics 257–261
    - drug discovery 252
    - drug targets 257
    - inhibitors 251, 255
    - promiscuity 255
    - schematic presentation 252
    - structural considerations 251
  - malaria transmission 267
  - malaria vaccine initiative (MVI) 34
- mammalian cell-based assays 255
- mammalian cell lines (COS-7/HEK-293) 345
- mammalian cells 25, 240
- mammalian glutathione (GSH) reductase 87
- mammalian glycogen synthase kinase (GSKs) 264
- mammalian homologs 218
  - glutathione reductase 218
  - thioredoxin reductases 218
- mammalian-infective stage 233
- mammalian latrophilin receptor 345
- mammalian multidrug resistance
  - proteins 25
    - MRP 2 25
    - MRP1 25
    - MRP3 25
- mammalian protein kinases, inhibitor research 241
- mammalian redox mediator glutathione 211
- mammalian species 187
- Mannheimia haemolytica* 443
  - genome sequencing 443
  - M7/2 genome 447
  - PHL213 441

- schematic map 448
- strains 444, 456
- Mannich bases 219
- inhibitors 312
- Marek's disease virus 167
- Mastomys coucha* 343
- maternal immunity 167
- matrix metalloproteases (MMPs) 190
- mitochondriate protozoa 76, 77, 78
  - *Entamoeba histolytica* 78
  - *Giardia* 78
- medicinal chemistry 10
- Medicines for Malaria Venture (MMV) 34, 179, 289, 301
- membrane-bound enzymes 69
- membrane-bound receptors 164
- membrane-bound subtilisin-like protease, SUB2 179
- MenB genome sequence 388
- meningococcal antigens 389
- MEP pathway, enzymatic steps 91
- MEROPS database 190
- messenger-independent, serine/threonine protein kinases 237
- metabolic pathways 75, 212, 277, 278, 285, 286, 287, 387
  - schematic presentation 287
- metabolic stability 324
- metabolite transporters 286
- metacaspase null parasites 198
- meta-genomics databanks 395
- metallo-dependent cysteine protease 188
- metazoan pathogens 19
- methicillin-resistant *Staphylococcus aureus* (MRSA) 398, 431
- methionyl tRNA synthetase (MetRS)
  - inhibitors 384
- methionine- $\gamma$ -lyase (MGL) isoforms 82
- methylene-containing derivatives 363
- methyl group donor 51
  - S-adenosyl-L-methionine 51
- mevalonate pathway 89
- microaerophilic/anaerobic conditions 361
- microarray analysis 382
- microbial genomics 380–381
  - sequences 442
- microbial surface components 391
- microbiological pathogens 160
- microbiological techniques 386
- microcrystalline cellulose triacetate (MCTA) 305
- microdialysis 433
- microtubules 18
- minimal chronic inflammatory cell 427
- minimum effective concentration (MEC) 359
- minimum inhibitory concentration (MIC) 455
- Ministry of Health in Malaysia 36
- mitochondria 360
  - electron transport system 88
- mitochondrial respiratory systems 360
  - respiratory chain 361
- mitochondrial trypanedoxin 216
- mitogen-activated protein (MAP) kinase 229–234
  - homolog 233
  - schematic presentation 231
  - signal transduction cascade 231
  - signaling cascade 256
  - structure 232
- mitosis regulators, *see* aurora kinase
- mitotic cyclin degradation 240
- molecular assays/cellular models 104
- molecular/biology techniques, 46
  - array 431
  - genomics 46
  - safety assays 103
  - scaffold 41
- molecular docking experiments, schematic presentation 48
- molecular modeling techniques 455
- monoclonal antibodies 392
  - auroxis/tefibazumab 391
- monomeric trypanothione synthetase 86
- moonlighting proteins 292
- multidrug-resistant (MDR) microorganisms 404
  - CL347 099 24
  - verapamil 24
- multidrug-resistant bacterial pathogens 376
- multidrug-resistant pathogens 397, 404
- multidrug-resistant strains 309
- multi-objective lead optimization process 122
- multiple sequence alignment 52
  - EST sequences 52
  - SAM synthetase sequences 52
- multiresistant bacterial pathogens 387
- multi-step enzymatic reactions 76
- MUMmer dot plot 444
- Mycelia sterilia* PF1022 340
- Mycobacterium tuberculosis* (MTB) 91, 160, 381, 415, 416
  - infection 170
  - light microscopy 416
  - scanning EM 416

**n**

- N-acetylglucosamine-enolpyruvyl reductase (MurB) 402
- N-acetylneuramic acid 388
- NADH-fumarate oxidoreductase 362
- NADH-fumarate reductase system 92, 93  
– schematic presentation 93
- NADPH 291  
– reoxidation 361
- N-alkyl-2-amino-1-phenyl-1-ethanethiosulfuric acids, antischistosomal activity 308
- narrow-spectrum antibiotics 12, 386
- natural ectoantiparasitics/anthelmintics 149
- natural immunity 162
- N-methyl-D-leucine 344
- N-methyl-L-leucine 340
- N-S-blocked glutathione monoester/diester derivatives 219
- N-terminal domain 266  
– lobe 251
- N-terminal nucleotide binding site 79
- neglected tropical diseases (NTDs), schistosomiasis 301
- nematode genes 11  
– larvae 364
- nematode ion channels 357  
– 4-aminobutyric acid (GABA) 357  
– glutamate-gated chloride channels 357  
– nicotinic acetylcholine receptors 357
- nematode nervous system 19, 94
- nephelometric method 155
- neuromuscular junction 19, 349
- neuronal/neuromuscular transmission 93
- neuron depolarization 94
- neurotransmitter receptors 19  
– ligand-gated anion channels 20  
– ligand-gated cation channels 19
- NeuTec pharma 391
- nicotinic agonists 17  
– imidazothiazoles 17  
– tetrahydropyrimidines 17
- nicotinic acetylcholine receptors (nAChRs) 12, 19  
– agonists 340
- nicotinic cholinergic agonists 4
- nicotinic receptors 20
- NIH Chemical Genomics Center 313
- NIMA kinase 264  
– family 264  
– Pfnck-1 264  
– Pfnck-3 265
- Nippostrongylus brasiliensis* 342
- nitrogen-containing bisphosphonates 77
- nonATP-binding pockets 252
- Non-Governmental Organization (NGO) 302
- non-live vaccines 168
- non-natural compounds, property values 149
- non-necrotizing granulomata 426
- non-peptide agonists/antagonists 13
- non-photosynthetic plastid-like organelle 89
- non-replicating persistence model (NRP) 435
- nonmethionine aminopeptidases 178
- nontoxic cysteine proteinase inhibitors 186
- nontoxic derivative anhydrotetracycline 379
- nosocomial pathogens 384  
– *Staphylococcus aureus* 378
- novel antimalarials approaches 291–292
- nuclear magnetic resonance (NMR) 111
- nucleated cells 163
- nucleic acid metabolism 377
- nucleic acid synthesis 211
- nucleotide binding oligomerization domain (NOD) receptors 164
- null mutants 232

**o**

- Oesophagostomum dentatum* 363
- optimization process 121
- optimization programs 125
- orphan protein kinases 268  
– Pfpk7 268  
– Pfpk9 269
- orphan receptor, HC110-R 344
- orthologous genes 65
- orthologous proteins 50
- osteoporosis 289
- oxidative stress 214, 217

**p**

- polar surface area (PSA) value 105, 142  
– molecular parameters 105
- O-phosphoserinesulphydrylase 85
- palladium complexes 219  
– Pd(5-nitrofuryl-3-acroleine thiosemicarbazone)<sub>2</sub> 219
- PAMPA double-sink protocol 141
- panton-valentine leukocidin (PVL), 396
- pantothenate kinase 418
- papain family 186  
– proteins 179
- para-amino salicylic acid 422, 423
- parasite encoded peptidases 190
- parasites hydroperoxide metabolism 216
- parasite-infected cell 190  
– cultures 266
- parasites/infective bacteria 106
- parasite membrane 196
- parasite metabolism 17

- parasite proteins 3
  - proteases 183
  - parasite redox pathway 312
  - balance 219
- parasite-selective CDK inhibitors 227, 237, 238, 241
- parasite-specific molecular targets 211
- parasite-specific pathway 213
- parasite-specific processes 285
- parasite-specific protein, trypanredoxin 213
- parasite target proteins 50
- parasites selective drug targets 75
- parasitic cysteine proteases 185
- parasitic diseases 160
- parasitic helminth 360
- parasitic infections 162
  - infectious diseases 45
  - material 126
  - vaccination strategies 162
- parasitic model systems 61
- parasitic nematodes 12, 17, 19, 23, 350, 357, 362
- parasitic protozoa 45, 241, 261
  - status/validation 177
- parasitic vaccines 168
  - species 11
- parasitophorous vacuolar membrane (PVM) 269
  - vacuole 267
- passive immunoprophylaxis 390
- Pasteurella aviseptica* 160
- Pasteurellaceae*-specific antibiotics 455
- Pasteurella multocida* 453
  - strains 469
- Pasteurella*-specific natural products 455
- pasteurestins, synthesis assignment 462
- pathogen associated molecular patterns (PAMP) 164
- pathogen-derived molecules, antigens 163
- pathogen-host interactions 375
- pathogenic bacteria 378, 376, 381, 388
- pathogenic processes 375
- pathogenic species 212
- pathogenic tubercle 160
- pathogenomics, definition 375
- pathogen recognition receptor (PRR) 163
- pathophysiological process 427
- paullone-based TryS inhibitors 220
- penicillin-binding proteins (PBPs) 402
- penicillin-resistant streptococci 396
- peptide deformylase 402
  - inhibitors 418
- peptide trypanothione 218
- peptidoglycan chains 398
- peptidoglycan synthesis 419
- peptidyl transferase 382
- permeability/lipophilicity values 135, 154
- peroxide bond 311
- peroxiredoxin-type trypanredoxin peroxidases 214
- pesticidal entities 363
- PF1022A structures 340, 341
  - anthelmintic activity 341
  - discovery/synthesis 340
- Pfmrk, autophosphorylation 262
- PfPKA-R protein 265
- PfPK5 inhibitors 263
- PfPK7 drug design 269
- phagocytic cells 197
- pharmaceutical research 135
- pharmacogenomic antibiotic screens 394
- pharmacokinetic data 434
- pharmacokinetic profile 131
- pharmacophore 325
  - approaches 325
  - based focused libraries 109
  - based virtual screening 328
  - 3D geometric arrangements 325
- pharyngeal muscle 20
- pharyngeal neuromuscular junction 350
- phenotype databases 50
- phenotypic classes 139, 141
  - determination 141
  - properties/assignment 139
- phenotypic drug resistance 431
- phenotypic/genotypic tests 385
- phenotypic screens 419, 421
- phenyl-thiazolylurea-sulfonamides 403
- phenylalanyl-t-RNA synthetase (PheRS) 383
  - inhibitor 382, 403
- phosphatase catalytic domains 228
- phosphinic acid derivatives 218
- phosphinic amides 313
- phosphohydroxypyruvate intermediate 83
- phosphoinositide interaction 266
- phosphonohydroxamate compounds 91
- phylogenetic analysis 445
- phylogeny/experimental data 380
  - expression profiles 380
  - proteome data 380
- physiology-based experiments 126
- physiology-based screens 125
- plant-derived metabolic pathways 286
- plant enzyme 77
- plant-like MKPs 228
- Plasmodium falciparum* 6, 178, 253, 284, 289, 309
  - chorismate synthase 90

- extrachromosomal DNA 285
- genome 285
- homology model 90
- infected RBCs 265
- plastid-like organelle, *see* Apicoplast
- plastid-localized targets 285
- plastid-specific enzyme 291
- platelet-derived growth factor receptor (PDGF-R) 229
- pleckstrin homology domain 266
- pleiotropic redox mediator thioredoxin 213
- polymerase chain reaction (PCR) 429
  - amplification 446
  - methods 445
  - molecular biology techniques 443
  - reaction 446
- PLP-binding pockets 82
- PLP-dependent enzyme, cysteine synthase 84
- pneumococcal strains 384
- polar surface area 104, 109
- polar surface components 105
- polyclonal/monoclonal antibodies 390
- polysaccharide conjugate vaccine 391
- polysaccharide intercellular adhesin 392
- post-discovery synergies 10–11
- post-genomic methods 386
- post-translational modifications 267
- potency-solubility-permeability triad 155
- potential drug targets 227
  - trypanosomatid protein kinases 227
- PPDK inhibitor 80
- PPi analogs 77
  - active site 78
  - carbonyldiphosphonate/bisphosphonates 77
- PPi-dependent enzyme 77
  - phosphofructokinase 77
- praziquantal analogs 302, 305
  - structure 304
- predictive cell assays 434
- pre-existing kinase-directed chemical libraries 241
- presynaptic latrophilin-dependent pathway 349
- primary lymphoid organ 164
- procyclic trypanosomes 237
- product development partnerships 34
- promoter elements 379
- promoter region, *see* Introns
- prophylactic drugs 165
- prophylactic/therapeutic vaccines 357
- prophylactic treatment 166
- protease inhibitors 184, 198
  - approaches 180
- protein biosynthesis 377, 382
- protein-coupled receptors 19
- Protein Data Bank (PDB), 3D structure database 50
- protein expression 375
- protein kinase drug discovery 250–251
- protein kinase families 249
- protein kinase inhibitors 240, 292
  - multiple approaches 253
  - opportunities/challenges 240
- protein-ligand complexes 91, 330, 334
  - interactions 333
- proteins sequences 182, 288
  - post-translational modifications 288
  - targets 336
  - 3D structures 336
- protein-splicing elements 66
- protozoan protein kinase targets 239, 251, 256
  - Aurora kinases (AUK) 239, 240
  - glycogen synthase kinase-3 (GSK-3) 239
- protein kinases 218, 228, 230, 241, 264
  - pharmacological inhibitors 230
- protein phosphatase activity 228
- proteome data 382
- proteomic methods 291
- proton motive force 360
- protozoan blood parasite 159
  - *Theileria parva* 159
- protozoan parasite 6, 7, 184, 188, 197, 211, 241 277
  - *Entamoeba histolytica* 184
  - *Plasmodium falciparum* 277
  - *Leishmania* 35
- protozoan/helminth parasites 182
- protozoan/mammalian kinases 241
- protozoan/worm parasites 75
- Pseudomonas putida* 82
- public-private partnerships (PPPs) 34, 117, 179, 302
  - drug discovery 34, 117, 179, 302
- pulmonary arteries 343
- pulmonary infectious diseases 421
- pulmonary lymph nodes 433
- pulmonary surfactant 397
- pulsed-field gel electrophoresis 443
- purine-derived nitriles 190
- putative components 196
- putative cysteine proteases 182
- putative papain-like protease, SERA8 179
- putative peptidases 190
- putative protein 182
- pyruvate dehydrogenase 288, 290

- pyruvate ferredoxin oxidoreductase  
   (PFOR) 80, 81  
   – dehydrogenase 80  
   – H-bond network 81  
   – reaction 81  
   – recognition 80  
   – thiamine pyrophosphate cofactor 81  
 pyruvate-forming reaction 78  
 pyruvate oxidative decarboxylation 81  
 pyruvate phosphate dikinase 77
- q**
- quantitative structure-activity relationship  
   (QSAR) 47, 302  
 quinol-fumarate oxidoreductase (QFR) 361  
 quinone binding site 93  
 quinupristin/dalfopristin-resistant  
   strains 399  
 quinone derivatives 93
- r**
- radical derivatives 81  
 radiolabeled inhibitors 181  
 rational drug design 51  
   – development 160  
   – discovery programs 59  
   – SAM synthetase 51  
 RCSB Protein Data Bank 326  
 real-time PCR assays 185  
 receptor-ligand interactions 161  
 receptor-mediated endocytosis 189  
 recombinant DNA technology 169  
 recombinant enzymes 252  
   – oncosphere antigen 169  
 recombinant parasites 232  
 redox cyclers 212  
 Reformatsky aldol reaction 467  
 resistance-breaking anthelmintic  
   compound 358  
 respiratory chain 104, 361  
   – anthelmintic drug target 359  
   – inhibitors 359  
 restriction enzymes 447  
 reticuloendothelial system (RES) 167  
 rhomboid intramembrane protease 179  
 rhomboid proteins 187  
 rhoptry protein 187  
 ribonucleotide reductase 217  
   – reduction 213, 217  
 ribosomal proteins 382  
 ring systems 303, 460  
 risk management 59  
 RNA-based hybridization 385  
 RNA dot blot analysis 182
- RNA interference (RNAi) technique 12, 46,  
   65, 312  
   – systems 66  
 Roll Back Malaria (RBM) 278  
 root mean square deviation (RMSD)  
   method 331, 53  
   – measures 331  
   – value 53  
 ruminant production systems 190  
 russujaponols, structures 459
- s**
- S-adenosyl-L-methionine synthetase 51, 53,  
   54  
   – model structure 53, 54  
   – sequences 51  
 Saharan African countries 189  
*Salmonella* infections 380  
 SAT isoforms 83  
 scanning electron microscopy (SEM) 216  
 schistosome parasites 311, 312  
   – drug discovery 315  
   – genome sequence 312  
   – redox cascade 312  
*Streptococcus pneumoniae* 383  
 Schistosomiasis Research Unit 306  
 schizogony/gametocytogenesis 256  
*Schizosaccharomyces pombe* cdc2 mutant 264  
 Scientific Advisory Committee (SAC) 37  
 scoring process 332  
 screening cascade 102, 106  
 screening library 109  
 semi-automated medium-throughput  
   phenotypic screening 314  
 semisynthetic artemisinin derivatives 301  
 semisynthetic derivative 343  
 semisynthetic lipoglycopeptide 398  
 semisynthetic pristinamycin derivatives 399  
 sensory neurones 20  
 sequencing technologies 390  
 serine-aspartate (SD) repeat-containing  
   proteins 392  
   – SdrD 392  
   – SdrE 392  
   – SdrG 392  
 serine O-acetyltransferase 82  
 serine proteases 183, 184, 198  
   – activities 179  
   – inhibitors 183, 198  
 serine proteinases 187  
 serine/threonine protein kinases 229, 234  
 sexually transmitted disease (STD) 182  
   – *Trichomonas vaginalis* 181  
 sheep gastrointestinal nematode 20

- Shikimate biosynthetic pathway 89  
 – erythrose-4-phosphate 89  
 – phosphoenolpyruvate 89  
 shikimate kinase 418  
 sialic acid-binding protein 179  
 signaling pathways 253  
 signal peptides 196  
 signal transduction cascade 229, 347  
 single-dose therapies 313  
 single nucleotide polymorphism (SNP) 23  
 single strand conformation polymorphism (SSCP) 386  
 site-directed mutagenesis 84, 90  
 – experiments 86  
 sleeping disease, *see* HAT  
 SLO-1 channel subunit structural cartoon 349  
 SLO-1-dependent pathway 349, 352  
 SLO-1 pathway 20  
 – mutants 20  
 small molecule discovery center (SMDC) 316  
 SNIP-SNP mapping techniques 349  
 solid sclerotic granuloma 426  
 solvent-accessible surface areas 365  
 southern blot analysis 182  
 SPACE primers 446  
 spastic paralysis 20  
 species-specific targets 11  
 spindle-shaped flagellates 197  
 sporozoites 177  
*Staphylococcus aureus* 391  
 state-of-the-art 301  
 – biochemical methodology 455  
 – validation system 66  
 stem cell factor receptor 229  
 structural/metabolic drug targets 18  
 structural/spectroscopic data 90  
 structure-activity relationship (SAR) 100, 254, 362  
 structure-based VS methods 327, 335  
 structure-related parameters 130  
 substrate binding sites 78  
 subtilisin-like serine protease 179  
 subunit vaccines 168  
 sugar acids 389  
 – galacturonate 389  
 – gluconate 389  
 sulfur-containing amino acids 81  
 – deamination 81  
 – dethiomethylation 81  
 – metabolism 76, 81, 84  
 superoxide radical 219  
 surface-associated proteins 388, 390  
 surrogate assays 40  
 Swern oxidation 462  
 synaptic proteins 238  
 syntenic relations gap closure 444  
 synthetic antibiotic, 453, 454  
 – fluoroquinolones 454  
 – prontosil 453  
 – quinolones 454  
 synthetic antiparasitic drugs 4  
 synthetic dyes 3  
 synthetic libraries 383  
 synthetic optimization 104  
 synthetic tetrahydroquinoline 308  
 – oxamniquine 308  
 synthetic trioxolanes 309, 310  
 – antischistosomal activity 310  
 systems biology/metagenomics 386, 387
- t**
- T-helper cells 164  
*Theileria. annulata* peptidases 190  
 – secretion 191–195  
 T4 DNA ligase 446  
 target-active compounds 62  
 target-associated toxicity 126  
 target-based antibacterial drug discovery 59, 99, 418  
 – approach 69  
 – assays 70, 100  
 – mode of action 69  
 – programs 60  
 target-based screening 99, 106, 107  
 – drug identification 99  
 – focused libraries 109  
 – lead toxicity 102  
 – library attrition 110  
 – library design 108  
 – programs 65  
 target-directed resistance mechanisms 17  
 target identification techniques 64–65  
 target-inhibitor complex 330  
 target parasites 62  
 target product profiles (TPPs) 38, 314  
 target selected treatment (TST) 26  
 target-specific toxicity 70  
 tautomeric/ionization states 328  
 TB 415, 432  
 – chemotherapy 432  
 – drug discovery 415, 421  
 TBDPS-ether 465  
 TCA cycle 284  
 TDR program 9  
 temperature-inducible GAL4 transcription activation 68  
 tetrahydropyrimidines pyrantel 340

- thiol metabolism 86
  - thiol redox enzymes 312
  - thioredoxin glutathione reductase (TGR)-specific double-stranded RNA 312
  - thioredoxin-related protein 213
  - Theileria* genome 190
    - cell lines 197
  - Theileria* peptidase 196
  - Theileria* signalase 196
  - thiamine pyrophosphate (TPP) 80
    - synthesis 289
  - thienopyrimidine analogues 362
  - thin-walled oocysts 188
  - tick drug 121
  - toll-like receptors (TLR) 164
  - Toxoplasma gondii* 168, 186
    - genome project 186
  - transcuticular diffusion 126
  - transdermal compounds 152
  - transgenic RNAi system 66
    - induction 67
  - translational/rotational orientation 331
  - transmission electron microscopy (TEM) 216
  - transposon mutagenesis 65, 69
  - trans-sulfuration pathway 82
  - trehalose-6-phosphate synthase 327
  - Trichomonas vaginalis* 181
  - trichostrongylid parasite 358
    - *Haemonchus contortus* 358
    - *Teladorsagia circumcincta* 358
  - tritium-labeled PF1022A 344
  - tRNA aminoacylation reaction 384
  - t-RNA synthetases 403
  - tropical diseases 120
    - Chaga's disease 120
    - onchocerciasis 120
    - schistosomiasis 120
  - Trx-dependent pathways 312
  - TrxR/GR-dependent pathways 312
  - trypanocidal drugs 211
  - trypanosomal glutathione reductase 213
  - Trypanosoma cruzi* 35, 180
    - active site 87
    - trypanothione reductase
  - trypanosomatid CDKs 235, 237
  - trypanosomatid family 211
  - trypanosomatid parasites 227, 235, 236
  - trypanosomatid protein kinases 227
  - trypanosomatid protozoa 86, 227, 228
    - trypanothione metabolism 86
  - trypanosomatid species 228
    - *Trypanosoma brucei* 177
  - trypanosome alternative oxidase (TAO) 87
  - trypanothione-dependent peroxidase system 214
  - trypanothione reductase (TryR) 86, 213, 312
  - trypanothione-related enzymes 215
    - genetic manipulations 215
    - inhibitors 219
  - trypanothione synthetase (TryS) 211, 213
  - trypanothione system 87, 212, 213, 214, 215, 216, 220
    - inhibitors 220
    - schematic presentation 214
  - TryR inhibitors 219, 221
  - TryS inhibitors 218, 219
  - TSH motif 262
  - tuberculosis 415, 432
    - chemotherapy 432
    - drug discovery 415, 421
    - gaps 415
    - issues 415
  - tuberculous necrotizing granuloma 429
  - tubulin-like GTPase, FtsZ 402
  - TXY-motifs 231, 232
  - tyrosine kinase-like kinases 229
- u**
- UAS/GAL4 system 66, 67, 68
  - ubiquitin-conjugating enzyme 269
    - PfUBC13 269
  - UCSF Sandler Center for Basic Research 315
    - screen workflow 315
  - ultrasonic treatment 168
  - UNICEF 278
  - unicellular parasite 177
    - plasmodium 177
  - United Nations Development Program 278
  - University of California San Francisco (UCSF) 314
  - $\alpha, \beta$ -unsaturated ester 462
  - urinary tract infection (UTI) 389
- v**
- vaccination 166
  - vaccine adjuvants 170
  - vaccines/vaccination protocols 161
  - vancomycin-resistant enterococci (VRE) 403
  - variable surface glycoprotein (VSG) 238
  - vector-borne parasitic disease, HAT 189, 197
  - vector-transmitted diseases 165
  - ventral cord interneurons 20
  - vertebrate-specific neurotoxic protein 345
  - veterinary anthelmintic drug 120
  - veterinary anticoccidial drug 120
  - veterinary antiparasitic drug 118, 121, 127, 140, 147

- approaches 121
  - discovery programs 7
  - drug discovery 119, 135
  - function-based approach 124–125
  - historical strategies 118
  - impact 7
  - interactions 119
  - mechanism-based approach 123–124
  - physiology-based approach 125–126
  - veterinary-approved drugs 9
  - veterinary-driven development program 10
  - veterinary market 9
  - veterinary nematodes 358
  - veterinary oral ectoparasiticide 121
  - veterinary parasite 4, 5
  - veterinary pharmaceuticals 155
  - vinyl sulfone-based inhibitors 185, 186
  - viral vectors 169
  - virtual screening process 323, 326
    - 2D property-based ligand profiles 324
    - descriptor-based similarity measures 325
    - pharmacophore approaches 325
    - protein-ligand-based methods 325
  - virulence-associated genes 389
  - virulent strain 160
  - virus vaccines, development 160
  - visceral leishmaniasis 35, 36
    - black sickness/kala-azar 35
  - voltage-activated potassium channels 349
  - voltage-gated calcium channel 19
  - voltage-gated potassium channel 20
- w**
- Waals energy 333
  - Walter Reed Army Institute of Research (WRAIR) 305
  - web-linked based portal 41
  - whole-cell assays 8, 424
  - whole-genome shotgun sequencing 443
    - projects 442
  - whole-organism targets 110
  - Wittig reaction 467
  - World Health Organization (WHO) 18, 212, 278, 227, 302, 313
- x**
- XA-induced gamete formation 267
  - xestoquinone inhibitor 264
    - PfPK5 264
  - X-ray crystallography 80
  - X-ray diffractometry method 341
  - X-ray structures 326
- y**
- Yersinia pestis* 45
- z**
- Ziehl-Neelsen acid-fast staining 425

